Brussels, Belgium

Michel R Jans

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignee: G.d. Searle & Company. Active years: 1991-1993.


% Patents Active = 100.0


Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 86(Granted Patents)


Company Filing History:


Years Active: 1991-1993

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michel R Jans: Innovator in Cognitive Enhancement

Introduction

Michel R Jans is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cognitive enhancement through his innovative research and development. With a total of 3 patents, Jans has focused on compositions that aim to improve memory and learning capabilities.

Latest Patents

Among his latest patents, one notable invention is a composition containing D-cycloserine and D-alanine for memory enhancement. This composition is designed for use in memory and learning enhancement or for the treatment of cognitive disorders and psychotic disorders. It provides reduced adverse side effects typically associated with chronic D-cycloserine use, making it a promising option for those in need of cognitive support.

Career Highlights

Michel R Jans is associated with G.D. Searle & Company, where he has been able to apply his expertise in developing innovative solutions for cognitive enhancement. His work has garnered attention in the scientific community, contributing to advancements in the treatment of cognitive disorders.

Collaborations

Jans has collaborated with notable colleagues, including Alex A Cordi and Michel R Franz. These partnerships have allowed for a rich exchange of ideas and have furthered the development of his innovative compositions.

Conclusion

Michel R Jans stands out as an influential inventor in the realm of cognitive enhancement. His work continues to pave the way for new treatments that can significantly improve the quality of life for individuals facing cognitive challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…